CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023

Dec 12, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-08

Reporting Person: GRANDE ALICIA (VP, Treasurer and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-08	Common stock, par value $0.001 per share	M	40000	$1.13	Acquired	90557	Direct
2023-12-08	Common Stock, par value $0.001 per share	S	20000	$14.25	Disposed	70557	Direct
2023-12-08	Common Stock, par value $0.001 per share	S	20000	$14.30	Disposed	50557	Direct
2023-12-11	Common Stock, par value $0.001 per share	M	60000	$1.13	Acquired	110557	Direct
2023-12-11	Common Stock, par value $0.001 per share	S	30000	$13.74	Disposed	80557	Direct
2023-12-11	Common Stock, par value $0.001 per share	S	30000	$13.786	Disposed	50557	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-08	Options to purchase common stock	$1.13	M	40000	Disposed	2024-01-03	Common Stock (40000)	Direct
2023-12-11	Options to purchase common stock	$1.13	M	60000	Disposed	2024-01-03	Common Stock (60000)	Direct

Footnotes

F1: Ms. Grande sold the shares on the open market, for personal reasons, and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a a result of any disagreement with the Company.

F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.74 to $13.745 per share.

F3: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.78 to $13.79 per share.

F4: Options vested in three annual tranches beginning on January 3, 2018.